Diagnostics
Microarray differentiates wild-type and drug-resistant hepatitis B in serum
Published in Hepatitis Weekly, April 18th, 2005
According to recent research published in the Journal of Viral Hepatitis, "during the course of lamivudine administration in hepatitis B virus (HBV)-infected patients, a dynamic development of the viral population in serum is observed. Total HBV level is initially reduced, then lamivudine-resistant mutants appear, and finally, the viral level is increased. All methods of mutant detection so far described can only identify mutants in the serum, and cannot determine the proportion of those mutants."
"In this paper, we report the development of a novel technique that can...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-04-18)
More Articles from Hepatitis Weekly
- Allergy and Immunology
Mimicry by hepatitis C virus envelope protein E2 allows immune escape - Oncology
Environmental factors modify genetic susceptibility to primary liver cancer - Transplant Medicine
Liver donor-specific IFN-gamma-producing cells denote HCV recurrence risk - Zoonosis
Gibbon hepatitis B infections hamper prevention efforts in South-East Asia - Business & Finance
Cubist issues common stock in exchange for royalty rate reduction - Business & Finance
Genetics company reports on "solid progress" during second quarter - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
